A voluntary nationwide recall of 168,768 physician sample packs of Taytulla capsules was issued by the Dublin-based drug maker. The action came in the wake of a discovery by a physician of a package in which four non-hormonal placebo capsules replaced active capsules in the first four days of therapy.
India-based Omega Healthcare has categorically stated that the growth of data analytics and cloud intelligence firms in the Indian healthcare sector has little scope. The company plans to hire around 1,200 - 1,500 people for exploring emerging markets like the United Arab Emirates.
The annual meeting of the American Urological Association had Sesen Bio present its three-month data for its bladder cancer treatment Vicinium. This was Sesen Bio’s first readout following its name change from Eleven Biotherapeutics.
Serious security flaws were discovered in Philips, GE and Silex medical devices that, if exploited, could allow authorized access and let a hacker obtain elevated privileges, according to two separate U.S. Department of Homeland Security ICS-CERT alerts issued this month.
A clinical trial solution has been unveiled by DNAnexus that facilitates the integration of genomics data sourced from next-generation sequencing (NGS) into clinical studies. A cloud-based genomic data collection platform is offered by DNAnexus.
Mountain View, California startup - Qventus a healthcare management tech platform which uses artificial intelligence to improve hospital workflow, closed at $30 million in series B funding which will be used to expand its platform. The funding was led by Bessemer Venture Partners along with few other participants. Including this latest funding, Qventus bagged total $43 million.
According to reports, the biotechnology company Abpro has rescheduled its $96 million IPO, delaying a capital infusion it hoped would support the first clinical trials of its lead product candidates over the next year.
The team is focusing to make Alex, the voice assistant, more convenient and useful in the health-care sector, which requires regulations and data privacy set by the HIPAA – Health Insurance Portability and Accountability Act. The experts are aiming to work on diabetes management, assistance for mother, infants and the elderly.
It has been stated by the patients that Gilead concealed crucial information that the TDF drugs could trigger kidney and bone risks. A safer alternative in the form of TAF could have been incorporated while marketing Truvada and Atripla. The research into TAF was deliberately stopped and the drugs are not likely to be brought to the shelf in the near future.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.